Parvovirus B19 infection with rheumatologic manifestations: results from a multicentre Italian study
Authors' conclusion
This study provides the largest systematically collected multicentre cohort of adults with B19V infection referred to rheumatology during the post-pandemic European outbreak.
Study context
- Population
- Adults with parvovirus B19 (B19V) infection referred for rheumatologic evaluation, nine Italian rheumatology units, 2023–2024 post-pandemic resurgence85% confirmed diagnosis
- Participants
- 71 adults
- Outcome
- Clinical spectrum of adult B19V infection and clinical predictors of arthritis resolution
Methodological detailsmulticentre, nine Italian rheumatology units, standardised REDCap data collection
- Multicentre
- Nine Italian rheumatology units
- Standardised REDCap data collection
Main finding
As reported in the abstract
- Median age, years
- 43
- Female
- 72%
- Joint involvement (predominantly oligoarticular, often large joints)
- 96%
- Fever
- 65%
- Skin manifestations
- 61%
- Purpuric rash confined to pretibial region, sparing ankles and feet (patients)
- 9
- Symptom resolution (usually within one month)
- 87%
- GC use and faster resolution (Cox regression), HR 0.53; 95% CI 0.31-0.90
- p=0.020
Observational data: associations, not effects.
Original publication
Parvovirus B19 infection with rheumatologic manifestations: results from a multicentre Italian study. Clin Exp Rheumatol. Published 7 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →